Market Research Report
Asia Pacific Neurorehabilitation Device Market Forecast 2021-2028
|Published by||Inkwood Research||Product code||980915|
|Published||Content info||142 Pages
Delivery time: 2-3 business days
|Asia Pacific Neurorehabilitation Device Market Forecast 2021-2028|
|Published: January 11, 2021||Content info: 142 Pages||
The Asia Pacific neurorehabilitation device market is evaluated to grow with a CAGR of 16.22%, over the forecast years of 2021 to 2028. The rising investments by the government and private organizations, the growing prevalence of neurodegenerative diseases, and the increasing geriatric population, are factors attributed to the region's market growth.
The Asia Pacific neurorehabilitation device market is evaluated by assessing South Korea, Vietnam, Thailand, Australia & New Zealand, Indonesia, India, Japan, China, and the rest of the Asia Pacific. Eisai, a Japanese pharmaceutical company, announced an investment of nearly $1.04 billion, over the next ten years, considering the development of dementia treatments. This entails the target of launching three drugs capable of curing or reversing an individual's cognitive decline. Additionally, over 20% of Japan's population is above the age of 65 years, representing the highest proportion, globally.
On the other hand, according to the World Health Organization (WHO), the incidence rate for stroke accounts for 58, per 100,000, among India's population. Likewise, individuals over the age of 55, are more likely to be impacted by strokes. As per the State Ministry of Health, India's state health department decided to establish its foremost neurological rehabilitation center in Maharashtra. The establishment aims to offer facilities for patients with numerous neurological diseases and assist recovery from disabilities caused by conditions like spinal cord injury and brain stroke. As a result, these factors are projected to drive the Asia Pacific neurorehabilitation device market growth.
Some of the distinguished companies operating in the market include, NeuroStyle PTE Ltd, Medtronic PLC, Abbott Laboratories, etc.